Module 5
Substance Use Disorder
Medication for opioid use disorder reduces mortality substantially, the fifty-year privacy barrier to the data expired in February 2026, and an honest closing assessment.
By the end of this module, you will be able to:
- Explain why retention rather than initiation carries the mortality benefit
- State what the rewritten Part 2 rule changed and what it did not
- Apply a single test to judge whether a behavioral arrangement is genuinely value-based
- Treating Opioid Use Disorder Medication for opioid use disorder reduces mortality substantially. The gap between that evidence and what is delivered is among the largest in medicine. About 5 min
- The Privacy Rule and the Data For fifty years, federal law kept addiction records out of the medical chart for good reasons. That rule was rewritten, and compliance came due in February 2026. About 5 min
- Behavioral Health: An Honest Scorecard The capstone: we know what works clinically, we know payment exists, and the field has mostly measured spending instead of whether anyone got better. About 5 min
Module quiz
Answer all questions to see your score.
1. Why is retention the outcome that matters in opioid use disorder treatment?
A meta-analysis of 32 cohort studies found substantial mortality reduction during treatment versus time out of it, with the greatest reduction in the first four weeks.
2. What did the 2024 rewrite of 42 CFR Part 2 change?
Removing the segregation requirement dismantles the technical mechanism that kept behavioral data walled off. Compliance became mandatory February 16, 2026.
3. What is the practical test for any behavioral health risk arrangement?
It is not a high bar, and most arrangements to date have not cleared it.